Iran Press/ Iran News: Yesterday (April 5) Top Adviser to the Leader of the Islamic Revolution for International Affairs and Head of Massih Daneshvari Hospital said that Shahid Beheshti University managed to produce Favipiravir medicine.
Ali Akbar Velayati said that Favipiravir medicine received an ethics committee approval and after observing legal procedures was sent to Massih Daneshvari Hospital to treat COVID-19 disease patients.
Many international authorities are conducting a scientific research study on Favipiravir to increase the likelihood of treating COVID-19 patients in addition to Corona's official treatment program.
According to researches, medicine can expedite the patients’ recovery and reduce the duration of their hospitalization. However, the effects of this drug on severe and ICU patients still need further research.
If the result of a clinical test of the drug was confirmed as effective in the treatment of COVID-19 disease, the technology of manufacturing and formulating the drug inside Iran in both academic and private sectors are ready to be launched and used in medical centers.
Favipiravir was first introduced in 2011 by Toyama, Japan, as a type B influenza drug, and its use has been suggested for the treatment of coronavirus after the onset of the epidemic.
205/207
Read more:
Iranian researchers produce Favipiravir to treat COVID-19
